Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.

Bristol Myers Squibb’s dividend appears covered in the near term, with a 70% payout ratio and a 4.3% dividend yield. However, a looming patent cliff threatens future cash flows: Eliquis and Opdivo lose exclusivity in 2028, and together generated roughly half of last year’s revenue. The article is “cautiously optimistic” that the growth portfolio (e.g., Breyanzi/Opdualag, Sotyktu, Cobenfy) can sustain dividends into the decade, though a dividend cut later remains possible given $44.5B debt.

Analysis

BMY screens as a classic yield trap only if you ignore timing. Near-term dividend coverage is not the problem; the market question is whether the growth portfolio can keep operating leverage positive long enough to prevent the stock from becoming a slow-march de-rating story into the 2028 LOE window. With leverage still elevated, buybacks stay optional rather than material, so equity upside depends on proving replacement revenue rather than financial engineering.

The main second-order effect is competitive: every dollar of legacy erosion shifts bargaining power toward generic manufacturers and away from other high-yield pharma names that still have cleaner patent runways. If newer oncology and neuroscience assets keep compounding, BMY can remain a defensive income holding; if they stall, the market will begin pricing a forced dividend-reset scenario well before the actual cliff date. That means the stock is likely to trade on quarterly evidence of replacement, not on the headline yield.

The contrarian miss is that the dividend may stay intact while the equity still underperforms for years. A cut is not the base case, but the streak of annual raises is at risk if free cash flow remains lumpy, and that matters because income investors often bid the shares for the wrong reason. Falsifiers: sustained 2H26 free-cash-flow coverage of the dividend, accelerating uptake in the newer portfolio, and visible net-debt reduction; without those, the multiple stays capped.

Key Decisions for Investors

• No immediate outright trade: keep BMY on a watchlist rather than chasing the 4.3% yield; wait for 2H26 free-cash-flow confirmation and rebate normalization before adding exposure.
• For a bearish expression, use 12-18 month BMY put spreads rather than stock shorting; the thesis only works if growth portfolio execution disappoints, so define risk tightly and avoid paying up for near-term implied vol.
• Relative-value alert: long VTRS or TEVA versus short BMY only if channel checks show legacy-revenue erosion accelerating faster than new-product growth; this isolates patent-cliff beneficiaries from the cliff bearer.
• If you already own BMY for income, trim on any rally that prices the stock as a stable bond proxy; the upside case is capped until the market sees sustained replacement revenue, not just dividend coverage.